Rize Oncology (XCNQ:RIZE) Net Issuance of Preferred Stock : C$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Rize Oncology's net issuance of preferred for the three months ended in Dec. 2024 was C$0.00 Mil. The number is 0, which means that Rize Oncology has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Rize Oncology's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00 Mil.

Rize Oncology Net Issuance of Preferred Stock Historical Data

The historical data trend for Rize Oncology's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology Net Issuance of Preferred Stock Chart

Rize Oncology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Net Issuance of Preferred Stock

Rize Oncology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial												-	-	-	-	-

Rize Oncology Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Rize Oncology Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Rize Oncology's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Rize Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

RZONF:USA

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.rizeoncology.com

Rize Oncology Inc is is a biopharmaceutical company. The company is focused on the development of high-efficiency precision gene editing for human therapeutics applications. The company is also engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecules targeting soft tissue sarcoma and other cancers.

Executives

William James Garner	10% Security Holder, Director
Andre Pereira Fraga Figueiredo	Director

Rize Oncology Headlines

No Headlines